Tarsa Therapeutics, Inc. — Form D

Tarsa Therapeutics, Inc. of PHILADELPHIA, PA, a company, filed a Form D exempt-offering notice with the SEC on 2016-07-14. The offering totals $1.3M, of which $1.3M was reported sold. Industry: Biotechnology.

Offering

Filed: 2016-07-14
Form: D
Accession: 0001475030-16-000002
Industry: Biotechnology
Exemptions: 06b
Total offering: $1.3M
Amount sold: $1.3M
Investors: 7
Date of first sale: 2016-06-29
Security types: debt
Revenue range: Decline to Disclose
SEC file number: 021-266953

Issuer

Name: Tarsa Therapeutics, Inc.
CIK: 0001475030
Entity type: Corporation
Jurisdiction: DELAWARE
Incorporated: 2009
Address: 8 PENN CENTER, PHILADELPHIA, PA, 19103
Phone: 267-273-7940

Officers, directors & promoters (12)

Name	Role	Location
Derek Ferguson	Director	New York, NY
Richard Levy	Director	Chicago, IL
Eric Bednarski	Director	Boston, MA
James Tananbaum	Director	South San Francisco, CA
Lewis Geffen	Executive Officer	Cambridge, MA
Martin Edwards	Director	Boston, MA
Ashleigh Palmer	Director	Waltham, MA
RICHARD KOLLENDER	Director	LOWELL, MA
David Brand	Director	San Francisco, CA
David Brand	Executive Officer	San Francisco, CA
Gregory Lumpkin	Executive Officer	Philadelphia, PA
Matthew Rieke	Director	Philadelphia, PA

Other filings by this issuer (7)

Filed	Form	Offering	Sold
2017-07-24	D	$1.0M	$550K
2017-01-13	D	$1.6M	$1.6M
2016-02-19	D	$2.0M	$2.0M
2012-03-22	D	$28.0M	$13.8M
2011-04-21	D/A	$24.5M	$15.5M
2010-10-08	D	$8.5M	$3.5M
2009-10-27	D	$24.1M	$12.1M

More